Regulus Therapeutics Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regulus Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Regulus Therapeutics stock.
View analyst ratings for Regulus Therapeutics or view top-rated stocks.

Wall Street analysts have given Regulus Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Regulus Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Regulus Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Regulus Therapeutics.

Regulus Therapeutics Inc. (NASDAQ:RGLS) released its quarterly earnings results on Thursday, May, 13th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.09) by $0.01.
View Regulus Therapeutics' earnings history.

Regulus Therapeutics' stock was trading at $0.60 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RGLS shares have increased by 64.6% and is now trading at $0.9877.
View which stocks have been most impacted by COVID-19.

2 brokerages have issued twelve-month price objectives for Regulus Therapeutics' stock. Their forecasts range from $1.00 to $2.00. On average, they expect Regulus Therapeutics' share price to reach $1.50 in the next year. This suggests a possible upside of 51.9% from the stock's current price.
View analysts' price targets for Regulus Therapeutics or view top-rated stocks among Wall Street analysts.

2 employees have rated Regulus Therapeutics CEO Joseph Hagan on Glassdoor.com. Joseph Hagan has an approval rating of 49% among Regulus Therapeutics' employees. This puts Joseph Hagan in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Regulus Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of RGLS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Regulus Therapeutics investors own include Aduro Biotech (ADRO), Flexion Therapeutics (FLXN), Cytori Therapeutics (CYTX), PTC Therapeutics (PTCT), Novavax (NVAX), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP) and Trevena (TRVN).

Regulus Therapeutics trades on the NASDAQ under the ticker symbol "RGLS."

Regulus Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Endurant Capital Management LP (3.17%), Victory Capital Management Inc. (2.98%), Asymmetry Capital Management L.P. (2.65%), Ikarian Capital LLC (1.66%), Acadian Asset Management LLC (0.62%) and Geode Capital Management LLC (0.51%). Company insiders that own Regulus Therapeutics stock include Christopher Ray Aker, Daniel R Chevallard, Joseph P Hagan and Paul Edward Walker.
View institutional ownership trends for Regulus Therapeutics.

RGLS stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc.. Company insiders that have sold Regulus Therapeutics company stock in the last year include Christopher Ray Aker, and Joseph P Hagan.
View insider buying and selling activity for Regulus Therapeutics or view top insider-selling stocks.

RGLS stock was purchased by a variety of institutional investors in the last quarter, including Endurant Capital Management LP, Asymmetry Capital Management L.P., Victory Capital Management Inc., Ikarian Capital LLC, Acadian Asset Management LLC, Atom Investors LP, Geode Capital Management LLC, and Morgan Stanley.
View insider buying and selling activity for Regulus Therapeutics or or view top insider-buying stocks.

Shares of RGLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RGLS stock can currently be purchased for approximately $0.99.

Regulus Therapeutics has a market capitalization of $74.00 million and generates $10.01 million in revenue each year. The biopharmaceutical company earns $-15,730,000.00 in net income (profit) each year or ($0.45) on an earnings per share basis.

Regulus Therapeutics employs 23 workers across the globe.

The official website for Regulus Therapeutics is www.regulusrx.com.

Regulus Therapeutics is headquartered at 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121.

Regulus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-202-6300 or via email at [email protected]